Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Non-Current Liabilities: 2019-2025

Historic Total Non-Current Liabilities for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Mar 2025 value amounting to $211,683.

  • China SXT Pharmaceuticals' Total Non-Current Liabilities fell 46.89% to $158,263 in Q3 2025 from the same period last year, while for Sep 2025 it was $158,263, marking a year-over-year decrease of 46.89%. This contributed to the annual value of $211,683 for FY2025, which is 28.16% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Total Non-Current Liabilities of $211,683 as of FY2025, which was down 28.16% from $294,667 recorded in FY2024.
  • China SXT Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $365,823 during FY2023, with a 5-year trough of $6,292 in FY2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $294,667 (2024), whereas its average is $290,724.
  • Data for China SXT Pharmaceuticals' Total Non-Current Liabilities shows a maximum YoY crashed of 82.77% (in 2021) over the last 5 years.
  • Over the past 4 years, China SXT Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $6,292 in 2021, then reached $365,823 in 2023, then fell by 19.45% to $294,667 in 2024, then dropped by 28.16% to $211,683 in 2025.